Login to Your Account



ViroPharma Gives Cinryze Best Shot with $83M+ Halozyme Deal

By Tom Wall


Thursday, May 12, 2011
ViroPharma Inc., of Exton, Pa., decided to give Cinryze (C1 esterase inhibitor [human]) for routine prophylaxis against attacks of hereditary angioedema (HAE) its best shot, and has licensed recombinant human hyaluronidase enzyme (rHuPH20) technology from Halozyme Therapeutics Inc., of San Diego, to develop a subcutaneous formulation of the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription